Report of Foreign Issuer (6-k)
October 18 2018 - 7:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2018
Commission File Number 001-37846
CELLECT BIOTECHNOLOGY LTD.
(Translation of registrant’s name into
English)
23
Hata’as Street
Kfar
Saba, Israel 44425
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
The
first and second paragraphs and the “Forward Looking Statements” of the press release attached to this Form 6-K are
incorporated by reference into the registrant’s Registration Statements on Form S-8 (Registration No. 333-214817, 333-220015
and 333-225003) and on Form F-3 (Registration No. 333-219614 and 333-212432).
Attached hereto as Exhibit 99.1 and incorporated by reference herein
is a press release issued by the Registrant entitled “Positive Results of Orthopedic Treatment With The Use Of ApoGraft™
Enriched Stem Cells Derived from Fat Tissues.”
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
Cellect Biotechnology Ltd.
|
|
|
|
|
By:
|
/s/ Eyal Leibovitz
|
|
|
Name: Eyal Leibovitz
|
Date: October 18, 2018
|
|
Title: Chief Financial Officer
|
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Sep 2023 to Sep 2024